ANDA 214560, held by Solaris Pharma Corp. Tazarotene.
As of Nov 15, 2026, ANDA 214560 (Tazarotene), held by Solaris Pharma Corp, was first approved by FDA on Nov 24, 2025, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 24, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tazarotene0.05% ยท cream;topical | Tazarotene | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
